Image Credit: Glucotrack
Glucotrack announced that it has started enrolling a feasibility study for its implantable continuous blood glucose monitoring (CBGM) device. The study will include participants with both type 1 and type 2 diabetes, with data from the study expected to be available within 6-8 weeks.
According to the company, “unlike traditional continuous glucose monitors that measure glucose levels in interstitial fluid, Glucotrack’s CBGM measures glucose directly from blood, aiming to provide real-time readings without the lag time typically associated with interstitial glucose measurements. The CBGM is a long-term implantable device with no on-body external component, designed for three years of continuous, accurate blood glucose monitoring, offering a more convenient and less intrusive glucose monitoring solution.”